Background Transcatheter aortic valve replacement (TAVR) has increasingly emerged as one of the primary treatments for ...
New medical advancements are making surgery less invasive for those with Aortic Valve Disease. When the aortic heart valve ...
Early valve replacement surgery for very severe asymptomatic aortic stenosis was tied to lower long-term mortality risk ...
This marks the first dedicated transcatheter heart valve approved for high-risk patients with symptomatic severe AR.
JenaValve today announced the successful first cases and official U.S. commercial launch of its Trilogy heart valve system.
The final results of RECOVERY add support to addressing severe aortic stenosis right away rather than waiting for symptoms.
Medtronic (NYSE:MDT) today announced data from the ALERT trial aimed at addressing health disparities in structural heart care.
The Trilogy THV System is the first and only transcatheter device in the United States with a dedicated indication for high-risk aortic regurgitation (AR) - a historically underserved and ...
A chest-worn biosensor that features several measurement signals in one device reliably identifies the presence and severity ...
Transit Officer Paul DeGeorge thought his son was lying on him. Then he realized something much scarier was happening.
Solo Pace Incorporated, an emerging medical technology company, today announced the commercial release of the SoloPace FUSION(TM) Temporary Pacing System. The launch follows US Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results